AST-201

BIOLOGICAL2 trials

Sponsors

Aston Sci. Inc., Aptamer Sciences, Inc.

Conditions

Advanced Ovarian CancerCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungLiver NeoplasmsNeoplasms

Phase 1

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

RecruitingNCT06687941

Aptamer Sciences, Inc.Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms +1

Start: 2025-03-11End: 2028-05-01Target: 70Updated: 2026-03-27

Phase 2

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

Not yet recruitingNCT05794659

Aston Sci. Inc.Advanced Ovarian Cancer

Start: 2023-11-15End: 2027-11-15Target: 98Updated: 2023-07-20

Related Papers

Abstract 4114: AST-201 (pUMVC3-hIGFBP2 N-terminus) demonstrates anti-tumor effect in an ovarian cancer mouse model

Cancer Research2024-03-221 citations

817 AST-201 (pUMVC3-hIGFBP2 N-terminus) demonstrates anti-tumor effect in an ovarian cancer mouse model

Regular and Young Investigator Award Abstracts2023-10-312 citations